FDA Reverses Course, Grants Replimune Path to Resubmit Melanoma Drug
Summary
Replimune has secured an agreement with the FDA to resubmit its advanced melanoma treatment for approval, marking a significant reversal after two prior rejections. This development follows the recent departure of former FDA Commissioner Marty Makary, suggesting a shift in agency priorities. The previous rejections in July 2025 and April 2026 led to job cuts and a substantial stock price decline. This new path offers a critical lifeline for Replimune's lead drug candidate, RP1, and could materially impact the company's future. The company expects to resubmit the application in the coming days.
At the time of this announcement, REPL was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $386.4M. The 52-week trading range was $1.50 to $13.24. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.